Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189371
Status:
TERMINATED
Last Update Posted:
2005-09-19
First Post:
2005-09-13
Brief Title:
Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer Cancer of the Fallopian Tube or Peritoneum
Sponsor:
AGO Study Group
Organization:
AGO Study Group
Study Overview
Official Title:
Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer Cancer of the Fallopian Tube or Peritoneum
Status:
TERMINATED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with epithelial ovarian cancer fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinumtaxane containing chemotherapy have a significant chance of entering complete clinical remission but about 70 will eventually relapse Relapse more than 6 months following first line chemotherapy is regarded as platinumtaxane sensitive disease Reinduction chemotherapy with platinumtaxane is known to be an effective treatment option Therapy induced anemia is a common problem resulting in decrease of quality of life The rationale of this trail is to evaluate the effects of epoetin alpha on reduction of therapy induced anemia rate of transfusions and on quality of life
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None